ONC vs. REGN: BeOne Medicines vs. Regeneron Pharmaceuticals Stock Comparison
How do BeOne Medicines (ONC) and Regeneron Pharmaceuticals (REGN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BeOne Medicines (ONC) and Regeneron Pharmaceuticals (REGN) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Regeneron Pharmaceuticals (REGN) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ONC | REGN |
|---|---|---|
| Name | BeOne Medicines Ltd. American Depositary Shares | Regeneron Pharmaceuticals, Inc. |
| Country/Region | Switzerland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 46.49 billion USD | 93.55 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | February 3, 2016 | April 2, 1991 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ONC | REGN |
|---|---|---|
| Total Return (1Y) | 30.59% | 40.87% |
| Total Return (3Y, Annualized) | 30.15% | 5.15% |
| Total Return (5Y, Annualized) | 2.48% | 8.58% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ONC | REGN |
|---|---|---|
| Volatility (1Y, Annualized) | 35.90% | 34.08% |
| Beta (5Y) | 0.59 | 0.10 |
| Max Drawdown (5Y) | -68.89% | -59.69% |
| Avg. Volume (3M) | 405.29K | 772.95K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ONC | REGN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.73 | 1.07 |
| Sortino Ratio (1Y) | 1.15 | 1.70 |
Profitability
ROE (TTM)
Both BeOne Medicines (ONC) at 18.40% and Regeneron Pharmaceuticals (REGN) at 14.95% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.95%
- Max
- 109.18%
- REGN
- 14.95%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Regeneron Pharmaceuticals (REGN) at 28.51% keeps the most of each sales dollar — above its industry’s net margin range — and BeOne Medicines (ONC) at 13.86% also retains a top-quartile share.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.51%
- REGN
- 28.51%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both BeOne Medicines (ONC) at 22.15% and Regeneron Pharmaceuticals (REGN) at 40.46% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.46%
- Max
- 83.12%
- REGN
- 40.46%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ONC | REGN |
|---|---|---|
| ROE (TTM) | 18.40% | 14.95% |
| ROA (TTM) | 8.42% | 7.59% |
| Net Margin (TTM) | 13.86% | 28.51% |
| Operating Margin (TTM) | 22.15% | 40.46% |
| Gross Margin (TTM) | 89.39% | 46.73% |
Growth
Revenue Growth
Both BeOne Medicines (ONC) at 40.23% and Regeneron Pharmaceuticals (REGN) at 0.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Regeneron Pharmaceuticals (REGN) reports EPS growth of 8.19%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.
Growth Metrics
| Metric | ONC | REGN |
|---|---|---|
| Revenue Growth (YoY) | 40.23% | 0.99% |
| Revenue Growth (3Y CAGR) | 55.69% | 5.62% |
| EPS Growth (YoY) | -- | 8.19% |
| EPS Growth (3Y CAGR) | -- | 2.77% |
Financial Strength
Current Ratio (MRQ)
Both BeOne Medicines (ONC) at 3.55 and Regeneron Pharmaceuticals (REGN) at 3.35 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.35
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- REGN
- 3.35
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both BeOne Medicines (ONC) at 0.35 and Regeneron Pharmaceuticals (REGN) at 0.08 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.08
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- REGN
- 0.08
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ONC | REGN |
|---|---|---|
| Current Ratio (MRQ) | 3.55 | 3.35 |
| Debt / Equity (MRQ) | 0.35 | 0.08 |
| Net Debt / EBITDA | -2.80 | -1.17 |
Dividends
Dividend Yield (TTM)
BeOne Medicines (ONC) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a yield of 0.41%, ranking against industry peers normally.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.41%
- REGN
- 0.41%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
BeOne Medicines (ONC) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a payout of 8.18%, ranking against industry peers normally.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.18%
- REGN
- 8.18%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ONC | REGN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.41% |
| Dividend Payout Ratio (TTM) | 0.00% | 8.18% |
Valuation
P/E Ratio (TTM)
Regeneron Pharmaceuticals (REGN) at 19.99 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.99
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- REGN
- 19.99
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both BeOne Medicines (ONC) at 7.04 and Regeneron Pharmaceuticals (REGN) at 5.54 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.54
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- REGN
- 5.54
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Regeneron Pharmaceuticals (REGN) at 2.71 is valued about in line with its industry on P/B ratio, while BeOne Medicines (ONC) at 7.98 carries an above-peer premium to book — ONC is pricier on assets.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.71
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- REGN
- 2.71
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ONC | REGN |
|---|---|---|
| P/E Ratio (TTM) | 52.17 | 19.99 |
| P/S Ratio (TTM) | 7.04 | 5.54 |
| P/B Ratio (MRQ) | 7.98 | 2.71 |
| Free Cash Flow Yield (TTM) | 2.21% | 2.76% |